Publications

British journal of cancer

Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.

01-10-2022

Nature

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

01-09-2022

Nature genetics

Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.

01-06-2022

NPJ breast cancer

Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance.

06-05-2022

Nature medicine

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.

01-12-2020

Nature communications

A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.

16-01-2020

Nature communications

Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo.

06-11-2019

Nature

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.

01-08-2019

Bioinformatics (Oxford, England)

PRECISE: a domain adaptation approach to transfer predictors of drug response from pre-clinical models to tumors.

15-07-2019

Cell

Identifying Epistasis in Cancer Genomes: A Delicate Affair.

30-05-2019

PLoS computational biology

Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis.

01-10-2018

Bioinformatics (Oxford, England)

Comparative Network Reconstruction using mixed integer programming.

01-09-2018

Nature communications

Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.

30-11-2022

Nature communications

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.

02-11-2022

Cancer discovery

Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.

02-09-2022

iScience

Identifying mutant-specific multi-drug combinations using comparative network reconstruction.

19-08-2022

European urology

Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.

11-08-2022

Nature

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

01-08-2022

Molecular cancer therapeutics

Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists.

01-04-2022

Clinical cancer research : an official journal of the American Association for Cancer Research

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.

01-03-2022

Nature

Effective drug combinations in breast, colon and pancreatic cancer cells.

01-03-2022

Frontiers in immunology

The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.

07-01-2022

Proceedings of the National Academy of Sciences of the United States of America

Predicting patient response with models trained on cell lines and patient-derived xenografts by nonlinear transfer learning.

07-12-2021

Breast (Edinburgh, Scotland)

Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients.

01-12-2021

Clinical cancer research : an official journal of the American Association for Cancer Research

Ovarian Cancer-Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial.

01-12-2021

Statistics in medicine

Flexible co-data learning for high-dimensional prediction.

20-11-2021

Molecular cancer research : MCR

The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics.

01-10-2021

Nature medicine

Limited evolution of the actionable metastatic cancer genome under therapeutic pressure.

01-09-2021

Cell reports

The Cancer SENESCopedia: A delineation of cancer cell senescence.

27-07-2021

Molecular oncology

Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases.

01-07-2021

NPJ breast cancer

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ.

22-03-2021

Genome medicine

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

10-02-2021

Nature cancer

Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients.

01-02-2021

Clinical cancer research : an official journal of the American Association for Cancer Research

Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays.

01-09-2020

Radiology

Radiogenomic Analysis of Breast Cancer by Linking MRI Phenotypes with Tumor Gene Expression.

01-08-2020

Scientific reports

Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer.

02-07-2020

Nature communications

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.

22-06-2020

Cancer research

Endonuclease FEN1 Coregulates ERα Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer.

15-05-2020

Oncogene

Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression.

01-05-2020

PloS one

Approximating multivariate posterior distribution functions from Monte Carlo samples for sequential Bayesian inference.

14-03-2020

Oncoimmunology

Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.

03-03-2020

The EMBO journal

In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.

02-03-2020

Translational oncology

RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS-mutant colorectal cancer.

01-02-2020

Endocrine-related cancer

Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program.

01-02-2020

Proceedings of the National Academy of Sciences of the United States of America

Pancreatic cancer organoids recapitulate disease and allow personalized drug screening.

26-12-2019

eLife

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

19-12-2019

Nature communications

CD4⁺ T cell help creates memory CD8⁺ T cells with innate and help-independent recall capacities.

04-12-2019

European journal of radiology

Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?

01-12-2019

Science translational medicine

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.

09-10-2019

Nature medicine

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

01-07-2019

Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.

Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance.

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.

A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.

Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo.

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.

PRECISE: a domain adaptation approach to transfer predictors of drug response from pre-clinical models to tumors.

Identifying Epistasis in Cancer Genomes: A Delicate Affair.

Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis.

Comparative Network Reconstruction using mixed integer programming.

Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.

Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.

Identifying mutant-specific multi-drug combinations using comparative network reconstruction.

Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists.

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.

Effective drug combinations in breast, colon and pancreatic cancer cells.

The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.

Predicting patient response with models trained on cell lines and patient-derived xenografts by nonlinear transfer learning.

Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients.

Ovarian Cancer-Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial.

Flexible co-data learning for high-dimensional prediction.

The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics.

Limited evolution of the actionable metastatic cancer genome under therapeutic pressure.

The Cancer SENESCopedia: A delineation of cancer cell senescence.

Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases.

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ.

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients.

Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays.

Radiogenomic Analysis of Breast Cancer by Linking MRI Phenotypes with Tumor Gene Expression.

Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer.

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.

Endonuclease FEN1 Coregulates ERα Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer.

Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression.

Approximating multivariate posterior distribution functions from Monte Carlo samples for sequential Bayesian inference.

Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.

In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.

RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS-mutant colorectal cancer.

Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program.

Pancreatic cancer organoids recapitulate disease and allow personalized drug screening.

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

CD4+ T cell help creates memory CD8+ T cells with innate and help-independent recall capacities.

Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

This site uses cookies

CD4⁺ T cell help creates memory CD8⁺ T cells with innate and help-independent recall capacities.